Akari Therapeutics PLC (NASDAQ:AKTX)‘s stock had its “neutral” rating restated by equities researchers at Chardan Capital in a research note issued on Friday. They currently have a $2.50 target price on the biopharmaceutical company’s stock, down from their previous target price of $6.00. Chardan Capital’s price objective points to a potential downside of 27.49% from the stock’s current price.

A number of other brokerages have also weighed in on AKTX. William Blair lowered shares of Akari Therapeutics PLC from an “outperform” rating to a “market perform” rating in a research note on Friday, May 12th. Zacks Investment Research lowered shares of Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 target price (down previously from $33.00) on shares of Akari Therapeutics PLC in a research note on Monday, June 26th.

Shares of Akari Therapeutics PLC (NASDAQ AKTX) traded down 4.7597% during mid-day trading on Friday, hitting $3.4477. 21,749 shares of the company traded hands. The stock’s market capitalization is $40.60 million. The firm’s 50 day moving average price is $4.54 and its 200-day moving average price is $7.74. Akari Therapeutics PLC has a 1-year low of $3.37 and a 1-year high of $22.20.

ILLEGAL ACTIVITY NOTICE: “Chardan Capital Reiterates “Neutral” Rating for Akari Therapeutics PLC (AKTX)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/11/chardan-capital-reiterates-neutral-rating-for-akari-therapeutics-plc-aktx.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Hikari Power Ltd acquired a new position in shares of Akari Therapeutics PLC during the second quarter worth about $277,000. Baker BROS. Advisors LP acquired a new position in shares of Akari Therapeutics PLC during the third quarter worth about $4,229,000. Finally, NEA Management Company LLC acquired a new position in shares of Akari Therapeutics PLC during the second quarter worth about $6,100,000. 28.75% of the stock is owned by institutional investors.

Akari Therapeutics PLC Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.